Colchicine is a commonly prescribed medication. Overdose of colchicine is relatively uncommon but can be fatal. We report a 36-year-old female who survived from severe colchicine poisoning and was subsequently complicated with bronchiolitis obliterans with organizing pneumonia. The patient required a long period of mechanical ventilation but eventually recovered on supportive care. (Hong Kong j.emerg.med. 2011;18: 249-253) 36
Introduction
Bronchiolitis obliterans with organising pneumonia (BOOP) is a distinct clinicopathological entity and has characteristic inflammatory response features in the lung biopsy. BOOP has been reported as a secondary phenomenon in various clinical settings and to be associated with a variety of drugs. Colchicine is a commonly used drug for the treatment of gout contributed by its anti-inflammatory property. Clinical manifestations of colchicine poisoning were well described but no reported association of colchicine with BOOP was found in the literature. We report a case of severe colchicine poisoning in a young lady due to inappropriate self medication. The patient developed full-blown colchicine intoxication and prolonged respiratory failure. Transbronchial biopsy revealed BOOP pattern compatible with an acute lung injury induced by colchicine poisoning.
Case report
A 36-year-old lady, with previous history of anorexia nervosa, was admitted for severe diarrhoea for 2 weeks in October 2009. Her liver function was found deranged on admission with elevated alkaline p h o s p h a t a s e ( A L P , 1 7 2 U / L ) a n d a l a n i n e aminotransferase (ALT, 77 U/L) levels (reference range of ALP and ALP level: 40-105 U/L and 7-34 U/L respectively). Blood tests, including complete blood picture, renal function test, amylase level and spot blood glucose level were all normal. He platelet count decreased from 206 x 10 9 /L (reference range: 152-358 x 10 9 /L) to 14 x 10 9 /L on day 4 and her white cell count (WCC) dropped rapidly to 0.3 x 10 9 /L (reference range: 3.9-10.7 x 10 9 /L) on day 5. On further questioning, the patient admitted that she had taken an over-the-counter drug for foot pain recently and the drug was identified to be colchicine. Subsequent urine toxicology test showed the presence of colchicine and cimetidine only.
The patient was transferred to the intensive care unit (ICU) for the management of colchicine poisoning with severe leukopenia and thrombocytopenia. Physical examination on admission to ICU revealed moderate dehydration, Glasgow Coma Score 15/15, blood pressure 140/80 mmHg, pulse rate 130 beat per minute and body temperature 37 o C. Electrocardiogram (ECG) showed sinus tachycardia with normal QRS duration and corrected QT interval. Computerized tomography (CT) of abdomen was performed for persistent abdominal pain and showed only radiological features of paralytic ileus. Repeated doses of granulocyte colony-stimulating factor (G-CSF) were given for the leucopenia and her WCC increased to the normal range on next day after the first dose of G-CSF. Her platelet count responded slowly and was normalised around 1 week later. In view of her immunocompromised state, she was given broad spectrum antibiotic (piperacillin with tazobactam) empirically for treatment of possible underlying sepsis.
She developed respiratory failure and required intubation on the third day of her ICU stay. Her chest X-ray showed infiltrations over bilateral lung fields which were clear on admission (Figures 1a & 1b) . Initial bedside echocardiogram revealed good left ventricular (LV) contractility but repeated assessment showed global impairment of LV function with estimated ejection fraction (EF) only around 40%. Serum troponin I was also elevated (3.3 ng/mL with reference range <0.06 ng/ ml). The ECG showed poor R wave progression but no obvious ST segment changes. She also developed alopecia on day 7 ( Figure 3a ). In view of persistent respiratory failure, CT of thorax was done around 2 weeks after admission and revealed extensive consolidations, ground-glass opacities and bilateral pleural effusion (Figure 2a ). Cultures from respiratory tract specimens including sputum, bronchial aspirate and tracheal aspirate showed Candida albicans and yeast. Other bacterial cultures of blood, stool and urine were all negative. Her condition did not improve despite drainage of bilateral pleural effusion, switch of antibiotic to meropenem and addition of antifungal treatment, i.e. fluconazole. The antifungal treatment was subsequently changed to amphotericin B due to the deteriorating liver function. All the serological tests for viral infections and autoimmune diseases were negative. Transbronchial biopsy was done around 3 weeks after admission and showed BOOP pattern (Figures 3b & 3c) . Steroid therapy was not started as she subsequently d e v e l o p e d g a s t r o i n t e s t i n a l ( G I (Figure 2b) . Repeated echocardiogram showed improved LV function (EF of 58%) and ECG was normalised. She was discharged after a total of 81 days of hospitalisation.
Discussion
Colchicine, an alkaloid extract from Colchicum autumnale and its related species, is frequently prescribed for the treatment of acute gouty arthritis. It is also used in various other rheumatological and nonrheumatological conditions. 1 However, colchicine has a narrow therapeutic index and severe toxic side effects could result from accidentally excessive exposure. 2 Colchicine inhibits the cellular microtubule and has potent antimitotic activity. 3 These tissues with greatest mitotic activity (e.g. GI epithelial cells, hair follicles, and haematological stem cells) are mostly affected. Colchicine has a large volume of distribution in the body even in therapeutic dosing. Postmortem study in patients who died of colchicine intoxication revealed accumulation of colchicine in various organs in the body (including bone marrow, testicle, spleen, kidney, lung, heart and brain) with the highest concentration in the bone marrow. 4 The clinical presentations of colchicine poisoning were previously well reported and could be divided into three stages. The first stage is marked by the onset of GI symptoms mimicking gastroenteritis and is associated with excessive fluid losses. Stage 2 usually develops about 24 hours later and is characterised by multiorgan failure and bone marrow suppression. Patients recover from stage 2 would develop alopecia which represents the third stage of colchicine poisoning. 5 Deaths from colchicine overdose have been reported in the literature. 1 Most patient died from complications of multi-organ failure and cardiovascular collapse in stage 2. 6 The fatal dose was reported to be 0.8 mg/kg. 7 Diagnosis of colchicine overdose by detection of elevated plasma colchicine level in a patent presenting with unknown cause of multi-organ failure has also been reported. 8 Our patient exhibited the full-blown presentations of colchicine overdose, i.e. GI, haematological and dermatological complications, rendering measurement of plasma concentration of colchicine unnecessary.
Colchicine intoxication causes bone marrow suppression and results in profound leucopenia. Apart from gross hypoplasia and dysplasia, bone marrow examination in patients with colchicine poisoning could show the presence of toxic vacuolation and nuclear karyorrhexis. 9 Treatment of colchicine intoxication requires early recognition and intensive supportive care. Specific treatment options remain limited. Previous case reports demonstrated that the administration of G-CSF shortened the duration and ameliorated the severity of leucopenia. 10 In our patient, there was a dramatic increase in WCC shortly after the commencement of therapy. Animal study showed direct toxic effect of colchicine on myocardium 11 and colchicine specific Fab fragment had been reported to reverse the toxic effects of colchicine in patient with refractory shock after colchicine overdose effectively. However, it is still unavailable for general use. 12 Acute respiratory distress syndrome (ARDS) was known to be a complication of colchicine poisoning. Stapczynski et al had demonstrated normal pulmonary artery pressure in patient with radiographical features of pulmonary oedema after colchicine overdose. 5 The development of acute respiratory failure in our patient could be a combination of ARDS and pneumonia. Although, the isolations of Candida and yeast in the respiratory secretions could probably represent colonisations secondary to the administration of broad spectrum antibiotics, the absence of bacterial growth did not rule out an infective cause of her lung consolidation. Transbronchial biopsy in our patient revealed BOOP pattern with patchy polypoid and serpiginous fibroblastic proliferation predominantly in the airspace and there was no evidence of invasive fungal infection or malignancy.
BOOP is a distinct lung pathology which is characterised by fibroblastic proliferation involving bronchioles with extension in a continuous fashion into the alveolar ducts and alveoli representing an organising pneumonia. BOOP pattern occurs as a secondary process in different clinical conditions. 13 In contrast to the histological features of BOOP, the interstitial area, such as alveolar septa, is mainly involved in the proliferative phase of ARDS. 14 Many medications have been reported to be associated with BOOP in literature including amphotericin B. 15 Although amphotericin B had been given in our patient, she had persistent symptoms before the therapy and her symptoms gradually resolved despite the continuation of amphotericin B. Thus, her lung pathology was unlikely to be related to the amphotericin B treatment. To our knowledge, this was the first reported case of BOOP associated with colchicine overdose. The development of BOOP in our patient could be related to the ARDS secondary to the severe colchicine intoxication and the post-infectious lung injury could also be another triggering factor. Steroid therapy is the first-line treatment of BOOP. 13 However there were reported cases of spontaneously resolving symptoms and radiographic abnormalities in patients with druginduced BOOP after the cessation of the causative medications. 15 The spontaneous improvement without corticosteroid therapy in our patient could be related to the resolving toxicity of colchicine. Nevertheless, a direct casual relationship between the development of BOOP and the colchicine poisoning could not be confirmed in our patient because the patient's underlying pneumonia and immunocompromised state could also affect the clinical course and outcome.
Conclusion
Our case illustrated severe pulmonary complications associated with full-blown colchicine poisoning and is the first case report of BOOP associated with colchicine poisoning. It also demonstrated the danger of use of colchicine without appropriate professional counseling.
